Characterization of Vaccine-Enhanced Humoral Immune Responses Against Emergent SARS-CoV-2 Variants in a Convalescent Cohort
Pathogens · 2025
DOI: 10.3390/pathogens14010044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2025. Verfasst von Jared Sheehan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Antibodies, Viral, Immunity, Humoral. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, LSUHSC School of Medicine Research Enhancement Fund, LSUHSC School of Medicine Research Enhancement Program.
Abstract (Originalsprache)
Vaccination of COVID-19–convalescent individuals may generate ‘hybrid’ immunity of enhanced magnitude, durability, and cross-reactive breadth. Our primary goal was to characterize hybrid antibody (Ab) responses in a patient cohort infected with ancestral Wuhan-Hu-1 virus and vaccinated between 6 and 10 months later with the Wuhan-Hu-1–based BNT162b2 mRNA vaccine. We were particularly interested in determining the efficacy of neutralizing Ab responses against subsequently emergent SARS-CoV-2 variants. Sera collected at 3-monthly intervals over a period of 12 months were analyzed by ELISA for SARS-CoV-2 RBD–specific Ab responses, and also for neutralizing Ab activity using pseudovirus-based neutralization assays. We found that convalescent RBD-reactive IgG and IgA Ab responses did not decline significantly through 9 months post-diagnosis. These responses improved significantly following vaccination and remained elevated through at least 12-months. SARS-CoV-2 neutralizing Ab activity was detected in convalescent sera through 9 months post-diagnosis, although it trended downwards from 3 months. Neutralizing Ab activity against the Wuhan-Hu-1 strain was significantly improved by vaccination, to levels that persisted through the end of the study. However, sera collected from vaccinated convalescent subjects also had significant neutralization activity against Delta B.1.617.2 and Omicron variants that persisted for at least 2–3 months, unlike sera from unvaccinated convalescent controls. Thus, vaccination of Wuhan-Hu-1–convalescent individuals with the BNT162b2 vaccine improved and sustained protective neutralizing Ab activity against SARS-CoV-2, including cross-reactive neutralizing activity against variants that emerged months later.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
- Stanley S. Scott Cancer, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
- Department of Internal Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
ORCID-Profile: Jared Sheehan, Alistair J Ramsay
Förderung
- NIAID NIH HHS
- LSUHSC School of Medicine Research Enhancement Fund
- LSUHSC School of Medicine Research Enhancement Program
Zitieren
APA
Sheehan, J., Trauth, A. J., Hagensee, M. E., & Ramsay, A. J. (2025). Characterization of Vaccine-Enhanced Humoral Immune Responses Against Emergent SARS-CoV-2 Variants in a Convalescent Cohort. Pathogens. https://doi.org/10.3390/pathogens14010044
Vancouver
Sheehan J, Trauth AJ, Hagensee ME, Ramsay AJ. Characterization of Vaccine-Enhanced Humoral Immune Responses Against Emergent SARS-CoV-2 Variants in a Convalescent Cohort. Pathogens. 2025. doi:10.3390/pathogens14010044
BibTeX
@article{Sheehan2025,
author = {Sheehan, Jared and Trauth, Amber J and Hagensee, Michael E and Ramsay, Alistair J},
title = {Characterization of Vaccine-Enhanced Humoral Immune Responses Against Emergent SARS-CoV-2 Variants in a Convalescent Cohort},
journal = {Pathogens},
year = {2025},
doi = {10.3390/pathogens14010044}
}
EUVIMED